Azathioprine-induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase

British Medical Journal

Volumn 330, Issue 7487, 2005, Pages 350-351

  Konstantopoulou, M ^a   Belgi, A ^a   Griffiths, K D ^a   Seale, J R C ^a   Macfarlane, A W ^a  

^a YSBYTY GWYNEDD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CLOBETASOL PROPIONATE; CLOBETASOL PROPIONATE PLUS NEOMYCIN PLUS NYSTATIN; CORTICOSTEROID; DERMOVATE NN; NEOMYCIN; NYSTATIN; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ADULT; BLISTER; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; DRUG INDUCED DISEASE; DRUG MIXTURE; ENZYME DEFICIENCY; HUMAN; LETHARGY; MALAISE; MALE; PANCYTOPENIA; POMPHOLYX; PRIORITY JOURNAL; PRURITUS; REVIEW; SYMPTOM; THROMBOCYTE TRANSFUSION; TREATMENT FAILURE;

EID: 13744251731     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.330.7487.350     Document Type: Review

References (14)

1. Scerri L. Azathioprine in dermatological practice. An overview with special emphasis on its use in non-bullous inflammatory dermatoses. Adv Exp Med Biol 1999;455:343-8.
2. Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978;85:323-33.
3. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
4. Anstey A, Lennard L, Mayou SC, Kirby JD. Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review. J R Soc Med 1992;85:752-6.
5. Anstey A. Azathioprine in dermatology: a review in the light of advances in understanding methylation pharmacogenetics. J R Soc Med 1995;88:155-60P.
6. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995;131:193-7.
7. Holme SA, Duley JA, Sanderson J, Routledge PA, Anstey A. Erythrocyte thiopurine methyltransferase assessment prior to azathioprine use in the UK. Q J Med 2002;95:439-44.
8. El-Azhary RA. Azathioprine: current status and future considerations. Int J Dermatol 2003;42:335-41.
9. Wojnarowska F, Kirtschig G, Highet AS, Yenning VA, Khumalo NP. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002;147:214-21.
10. Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003;149:926-37.
11. Anstey AV, Wakelin S, Reynolds NJ. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 2004;151:1123-32.
12. Ford LT, Berg JD. Determination of thiopurine S-methyltransferase activity in erythrocytes using 6-thioguanine as substrate and a non-extraction liquid chromatographic technique. J Chrom B 2003;798:111-5.
13. Tan BB, Lear JT, Gawkrodger DJ, English JSC. Azathioprine in dermatology: survey of current practice in the UK. Br J Dermatol 1996;136:351-5.
14. Jackson AP, Hall AG, McLelland J. Thiopurine methyltransferase levels should be measured before commencing patients on azathioprine. Br J Dermatol 1997;136:133-4.